BCL2 and leukemia: Among other major results, TR presented selective efficacy against leukemia cells compared with peripheral blood mononuclear cells (PBMCs), and its cytotoxicity was observed even against leukemia model cells overexpressing antiapoptotic BCL-2/BCL-xL proteins.